<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36136760</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Co-administration of Oral Cholera Vaccine With Oral Polio Vaccine Among Bangladeshi Young Children: A Randomized Controlled Open Label Trial to Assess Interference.</ArticleTitle><Pagination><StartPage>263</StartPage><EndPage>270</EndPage><MedlinePgn>263-270</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciac782</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cholera remains a public health threat for low- and middle-income countries, particularly in Asia and Africa. Shanchol&#x2122;, an inactivated oral cholera vaccine (OCV) is currently in use globally. OCV and oral poliovirus vaccines (OPV) could be administered concomitantly, but the immunogenicity and safety of coadministration among children aged 1-3 years is unknown.</AbstractText><AbstractText Label="METHODS">We undertook an open-label, randomized, controlled, inequality trial in Dhaka city, Bangladesh. Healthy children aged 1-3 years were randomly assigned to 1 of 3 groups: bivalent OPV (bOPV)-alone, OCV-alone, or combined bOPV + OCV and received vaccines on the day of enrollment and 28 days later. Blood samples were collected on the day of enrollment, day 28, and day 56. Serum poliovirus neutralizing antibodies and vibriocidal antibodies against Vibrio cholerae O1 were assessed using microneutralization assays.</AbstractText><AbstractText Label="RESULTS">A total of 579 children aged 1&#x2012;3 years were recruited, 193 children per group. More than 90% of the children completed visits at day 56. Few adverse events following immunization were recorded and were equivalent among study arms. On day 28, 60% (90% confidence interval: 53%-67%) and 54% (46%-61%) of participants with co-administration of bOPV + OCV responded to polioviruses type 1 and 3, respectively, compared to 55% (47%-62%) and 46% (38%-53%) in the bOPV-only group. Additionally, &gt;50% of participants showed a &#x2265;4-fold increase in vibriocidal antibody titer responses on day 28, comparable to the responses observed in OCV-only arm.</AbstractText><AbstractText Label="CONCLUSIONS">Co-administration of bOPV and OCV is safe and effective in children aged 1-3 years and can be cost-beneficial.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION">ClinicalTrials.gov (NCT03581734).</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Islam</LastName><ForeName>Md Taufiqul</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases and Immunology, Menzies Health Institute Queensland and School of Pharmacy and Medical Science, Griffith University, Gold Coast, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Date</LastName><ForeName>Kashmira</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Ashraful Islam</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhuiyan</LastName><ForeName>Taufiqur Rahman</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Zahid Hasan</ForeName><Initials>ZH</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Shamim</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hossain</LastName><ForeName>Motaher</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khaton</LastName><ForeName>Fatema</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaman</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Nigel A J</ForeName><Initials>NAJ</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Immunology, Menzies Health Institute Queensland and School of Pharmacy and Medical Science, Griffith University, Gold Coast, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Abhijeet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chenhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weldon</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luby</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qadri</LastName><ForeName>Firdausi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03581734</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022121">Cholera Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022121" MajorTopicYN="Y">Cholera Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001459" MajorTopicYN="N" Type="Geographic">Bangladesh</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002771" MajorTopicYN="Y">Cholera</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bangladesh</Keyword><Keyword MajorTopicYN="N">OCV</Keyword><Keyword MajorTopicYN="N">OPV</Keyword><Keyword MajorTopicYN="N">co-administration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>12</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36136760</ArticleId><ArticleId IdType="pmc">PMC9839191</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac782</ArticleId><ArticleId IdType="pii">6711550</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol 2015; 10:791&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">25824845</ArticleId></ArticleIdList></Reference><Reference><Citation>Garon J, Seib K, Orenstein WA, et al. . Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines 2016; 15:693&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">26751187</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Weekly Epidemiological Record, 2014, vol. 89, 21 [full issue]. Weekly Epidemiological Record = Relev&#xe9; &#xe9;pid&#xe9;miologique hebdomadaire 2014; 89: 221&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis 2015; 9:e0003832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4455997</ArticleId><ArticleId IdType="pubmed">26043000</ArticleId></ArticleIdList></Reference><Reference><Citation>Legros D. Global cholera epidemiology: opportunities to reduce the burden of cholera by 2030. J Infect Dis 2018; 218(suppl_3):S137&#x2013;S40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6207143</ArticleId><ArticleId IdType="pubmed">30184102</ArticleId></ArticleIdList></Reference><Reference><Citation>http://www.who.int/mediacentre/news/releases/2017/partners-reduce-cholera/en/ Partners commit to reduce cholera deaths by 90% by 2030. Available at:</Citation></Reference><Reference><Citation>
Control GTFoC . Ending cholera&#x2014;a global roadmap to 2030. Available at: http://www.who.int/cholera/publications/global-roadmap/en/</Citation></Reference><Reference><Citation>Anh DD, Lopez AL, Thiem VD, et al. . Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 2007; 25:1149&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">17055622</ArticleId></ArticleIdList></Reference><Reference><Citation>Trach D, Clemens J, Ke N, et al. . Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997; 349:231&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9014909</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali M, Qadri F, Kim DR, et al. . Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial. Lancet Infect Dis 2021; 21:1407&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9759785</ArticleId><ArticleId IdType="pubmed">34146473</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya SK, Sur D, Ali M, et al. . 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2013; 13:1050&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24140390</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazevic V, Lappalainen S, Nurminen K, Huhti L, Vesikari T. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 2011; 29:8126&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">21854823</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski DA, Baudner BC, Singh M, O&#x2019;Hagan D T. Combination vaccines. J Glob Infect Dis 2011; 3:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068581</ArticleId><ArticleId IdType="pubmed">21572611</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One 2013; 8:e70409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3724941</ArticleId><ArticleId IdType="pubmed">23922988</ArticleId></ArticleIdList></Reference><Reference><Citation>Emperador DM, Velasquez DE, Estivariz CF, et al. . Interference of monovalent, bivalent, and trivalent oral poliovirus vaccines on monovalent rotavirus vaccine immunogenicity in rural Bangladesh. Clin Infect Dis 2016; 62:150&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4755336</ArticleId><ArticleId IdType="pubmed">26349548</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele AD, De Vos B, Tumbo J, et al. . Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2010; 28:6542&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786585</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaby P, Benn CS. Stopping live vaccines after disease eradication may increase mortality. Vaccine 2020; 38:10&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">31648913</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasir UN, Bandyopadhyay AS, Montagnani F, et al. . Polio elimination in Nigeria: a review. Hum Vaccin Immunother 2016; 12:658&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4964709</ArticleId><ArticleId IdType="pubmed">26383769</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol 2016; 1387:145&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci 1995; 754:289&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">7625665</ArticleId></ArticleIdList></Reference><Reference><Citation>Qadri F, Ryan ET, Faruque A, et al. . Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immun 2003; 71:4808&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165990</ArticleId><ArticleId IdType="pubmed">12874365</ArticleId></ArticleIdList></Reference><Reference><Citation>Qadri F, Wenner&#xe5;s C, Albert MJ, et al. . Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect Immun 1997; 65:3571&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC175508</ArticleId><ArticleId IdType="pubmed">9284121</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehlmoos TP, Uddin J, Sarma H. Impact of measles eradication activities on routine immunization services and health systems in Bangladesh. J Infect Dis 2011; 204(suppl_1):S90&#x2013;S7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21666219</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . SEA/RC67/35-WHO Regional Commitee for South-East Asia Report of the 67th session, Dhaka, Bangladesh, 9&#x2013;12 Sep 2014: WHO Regional Office for South-East Asia, 2015.</Citation></Reference><Reference><Citation>
Polio Disease and Poliovirus . Available at: https://www.cdc.gov/cpr/polioviruscontainment/diseaseandvirus.htm</Citation></Reference><Reference><Citation>Sutter RW, Bahl S, Deshpande JM, et al. . Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet 2015; 386:2413&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26388534</ArticleId></ArticleIdList></Reference><Reference><Citation>Azman AS, Luquero FJ, Ciglenecki I, Grais RF, Sack DA, Lessler J. The impact of a one-dose versus two-dose oral cholera vaccine regimen in outbreak settings: a modeling study. PLoS Med 2015; 12:e1001867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4549326</ArticleId><ArticleId IdType="pubmed">26305226</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanungo S, Desai SN, Nandy RK, et al. . Flexibility of oral cholera vaccine dosing&#x2014;a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone. PLoS Negl Trop Dis 2015; 9:e0003574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4357440</ArticleId><ArticleId IdType="pubmed">25764513</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanungo S, Paisley A, Lopez AL, et al. . Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 2009; 27:6887&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">19761838</ArticleId></ArticleIdList></Reference><Reference><Citation>Qadri F, Wierzba TF, Ali M, et al. . Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh. N Engl J Med 2016; 374:1723&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">27144848</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury F, Bhuiyan TR, Akter A, et al. . Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: revaccination after an interval of over three years of primary vaccination with a single dose of vaccine. Vaccine 2020; 38:1753&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7014297</ArticleId><ArticleId IdType="pubmed">31879124</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K, Kovacs SD, Vanderende K, et al. . Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial. Vaccine 2021; 39:5814&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9059229</ArticleId><ArticleId IdType="pubmed">34481702</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali M, Lopez AL, You Y, et al. . The global burden of cholera. Bull World Health Organ 2012; 90:209&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314202</ArticleId><ArticleId IdType="pubmed">22461716</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. General recommendations on immunization&#x2014;recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">21293327</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson WL, Pickering LK, Schwartz B, et al. . General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 2002; 51:1&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11848294</ArticleId></ArticleIdList></Reference><Reference><Citation>Maman K, Z&#xf6;llner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother 2015; 11:2132&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4635899</ArticleId><ArticleId IdType="pubmed">26075806</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>